|
A Study of ABT-751 in Patients With Renal Cell Cancer Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of ABT-751 in Patients With Renal Cell Cancer conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of ABT-751 in Patients With Renal Cell Cancer Clinical research trials and A Study of ABT-751 in Patients With Renal Cell Cancer medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of ABT-751 in Patients With Renal Cell Cancer. A Study of ABT-751 in Patients With Renal Cell Cancer Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of ABT-751 in Patients With Renal Cell Cancer clinical trial. Subjects often receive the most expert healthcare possible for their A Study of ABT-751 in Patients With Renal Cell Cancer condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of ABT-751 in Patients With Renal Cell Cancer  A Study of ABT-751 in Patients With Renal Cell Cancer
A Study of ABT-751 in Patients With Renal Cell Cancer
For Condition: Renal Cell Cancer
Status: Completed
Sponsor(s): Abbott Laboratories ,
Synopsis: The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with renal cell cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Renal Cell Carcinoma. - Recurrent tumor. - At least 6 weeks post-nephrectomy. - Not pregnant or breast feeding. - Able to tolerate normal activites of daily living. - No anti-tumor therapy within 4 weeks of the start of ABT-751 administration. - No CNS metastasis. - Adequate bone marrow, kidney, and liver function.
Total Enrollment:
Location and Contact Information:
US Oncology IncRaleigh Hematology Oncology Clinic
Cary, North Carolina, 27511
United States
US Oncology IncCancer Care Northwest-North
Spokane, Washington, 99218
United States
US Oncology IncRocky Mountain Cancer Centers
Denver, Colorado, 80218
United States
Oncology Hematology Group of South Florida
Miami, Florida,
United States
McGill University
Montreal, Quebec,
Canada
Arizona Cancer Research Center
Tucson, Arizona, 85712
United States
US Oncology IncDayton Oncology & Hematology P.A.
Kettering, Ohio, 45409
United States
Vanderbilt Ingram Cancer Center
Nashville, Tennessee, 37232-6307
United States
US Oncology IncCancer Centers of Florida, P.A.
Orlando, Florida, 32806
United States
US Oncology IncCancer Centers of the Carolinas
Greenville, South Carolina, 29615
United States
West Cancer Clinic
Memphis, Tennessee, 38120
United States
US Oncology IncFlorida Cancer Institute
New Port Richey, Florida, 34652
United States
B.C. Vancouver Cancer Agency
Vancouver, British Columbia, V5Z 4E6CAN
Canada
UCLA School of Medicine
Los Angeles, California, 90024
United States
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231
United States
US Oncology IncCancer Care Accociates-Mercy Campus
Oklahoma City, Oklahoma, 73120
United States
US Oncology IncOcala Oncology Center
Ocala, Florida, 34474
United States
US Oncology IncNorthwest Cancer Specialists
Vancouver, Washington, 98684
United States
McMaster University
E., Hamilton, Ontario, L8N 4A6
Canada
Clinical Trials + Research Associates
Montibello, California, 90640
United States
University of Chicago Medical Center
Chicago, Illinois, 60637-1471
United States
US Oncology IncTyler Cancer Center
Tyler, Texas, 75702
United States
Queen Elizabeth II Health Science Centre
Halifax, Nova Scotia, B3H2Y9
Canada
Additional Information:
Study ID Numbers: M02-416;
Study Start Date: September 2003
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00073112
Other Renal Cell Cancer Studies:
1. A Study of ABT-751 in Patients With Renal Cell Cancer
2. Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
3. Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
4. Gene Therapy in Treating Patients With Cancer
5. Avastin With or Without Erlotinib for Treatment of Metastatic Renal Cell Carcinoma
Related Studies:
Other Renal Cell Cancer Clinical Trials
Other Colorado Clinical Trials
Other Denver Clinical Trials
A Study of ABT-751 in Patients With Renal Cell Cancer
|
|
|
|
|
|
|
|
